Merck Serono and MDxHealth to develop cancer diagnostic test
6 July 2012 11:11 in Pharmaceutical Company Product News
Merck Serono is expanding its collaboration with MDxHealth to create a new diagnostic test for cancer.
The deal will involve the development of MDxHealth's MGMT diagnostic test as a means of identifying glioblastoma patients who might be more likely to benefit from cilengitide-based therapies in combination with temozolomide and radiotherapy.
This compound is currently undergoing phase III clinical testing against the aggressive brain cancer and has also shown promise as a potential non-small-cell lung cancer treatment.
Under the terms of the expanded alliance, Merck Serono will also be supporting MDxHealth's development and regulatory activities for the MGMT test, before coordinating its launch together with that of cilengitide.
Dr Annalisa Jenkins, head of global drug development and medical for Merck Serono, said: "We are hoping that this will help to improve the future treatment of patients with glioblastoma, a disease which today has high unmet medical needs."
Last month, Merck Serono and Compugen announced the launch of a new start-up company dedicated to the discovery and development of novel biomarkers.
Other news stories from 06/07/2012
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency